Member Info for Badsterman

Cox isn't bothered, they've just trousered £1.86 million for R&D and "brand development".

Income generation isn't part of the playbook.

Good points Top,

The other interesting event this week is that LUCY's six months deadline (for non-compliance with NASDAQ rules) expires on Friday.

They will have to boost the SP soon, or risk an appeal against a possible delisting.

What this IPO really needs is an announcement naming the food company who placed the 60,000lb order, with likely recurring revenue (see RNS from 22nd Dec).

EUDA have borrowed $500,000 dollars from Gilandi Limited, a British Virgin Islands company via a CLA with maturity dates of 31st Jan and 31st Mar 2024.

I assume they need this cash to keep afloat until the merger completes.

I might be wrong....

https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=317999141&type=HTML&symbol=EUDA&cdn=41708d83d16db596db8005627e69cbbb&companyName=Euda+Health+Holdings+Limited&formType=6-K&formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&dateFiled=2024-01-23

Sea,

What do you reckon Cliff wants the cash for? He just loaned £600,000 off LUCY.

Maybe he's spotted an opportunity too good to miss? Say, additional Microsalt inventory support for a big partner?

We can but hope.

PM,

"Bringing lots in and increasing costs further down the line is wrong and would show a complete lack of understanding"

Disagree; Dr Cox stated an ambition to bring in 3-4 new evaluation projects each year (ref: Half yearly report RNS), when he knew full well the funding position was precarious.

I'm anticipating you'll blame the failure to get 201 over the line for that.

This Board have pattern of promising but failing to deliver any shareholder value, you can't deny it.

PM,

Quote "you don't want too many compounds in the pipeline".

What? We are a drug development company, are we not?

The legacy assets have been farmed out to TRX, Ambrose and Stingray for nothing (as yet).

CLX was put into an SPV whilst shareholders were told "we are seeking partners" - it now requires another £400,000 R&D. Why waste money on an SPV before development was even completed?

We need more rounds in the chamber, otherwise we risk not hitting any targets at all.

PM

I'd have more respect for your posts if you didn't call out Porky for "deramping". He's been proven correct about the fundraise and the SP. So, why don't you eat a little humble pie?

Perhaps tell us why you think a deal for CLX is due when another £400,000 was raised for further R&D?

Or why you think the lab is such a success that they need more money for "brand establishment"?

When was the last actual agreement with a University to develop a new compound (as per the "strategy")?

This Board are lifestyle junkies and a change is needed.

🤣

Are you selling up OB? Your original post indicates even you've had enough.

OB,

The BOD are not listening, nor do they appear to have any intention of doing so.

Dr Cox, in particular, seems very adept at avoiding any challenge to his grip on power. Treharne continually fails to deliver in his role as "Corporate Development Manager".

None of the legacy assets have produced income, or a deal, despite Dr Hargreaves analysis and belief in 201.

Where are the promised evaluations? Why don't other universities want to work with Valirx? Why can't we sell the "strategy"? Why do Cytolytix and the lab need more money? What is the SAB actually doing?

The one dissenting voice (Stella) has been pushed out and the Board have now closed ranks, conveniently, just a couple of weeks after the fundraise.

Without news we'll probably be sub 5p next week.

We've just changed broker, probably because the last one ran out of fundraising options.

Is it any wonder investors are baying for blood?

OB,

The BOD are not listening, nor do they appear to have any intention of doing so.

Dr Cox, in particular, seems very adept at avoiding any challenge to his grip on power. Treharne continually fails to deliver in his role as "Corporate Development Manager".

None of the legacy assets have produced income, or a deal, despite Dr Hargreaves analysis and belief in 201.

Where are the promised evaluations? Don't other universities want to work with Valirx? Why can't we sell the "strategy"?

The one dissenting voice (Stella) has been pushed out. The Board have now closed ranks, conveniently just a couple of weeks after the fundraise.

Is it any wonder investors are annoyed?

"Very high risk" - is that the best analysis you can provide?

It's a diamond/valuable mineral mining operation, in a remote jurisdiction, in SA.

Did you consider such mining occurs with a gentleman's agreement over a cup of tea?

Dennis seems confident the Army will get to grips with the Zama Zama.

Diamonds by the end of February, marvellous!!

Of more interest is the purchase/loan of a magnetic separator combined into a deal with potential offtake partners.

I believe an inflection point is close.

Agreed,

The one person with any commercial acumen has dumped Valirx, in all probability due to clashing with Cox and Dilly over the lack of progress.

Meanwhile the perennial underachievers remain in situ, with plenty of time to plan their next fundraise.

The AGM can't come quick enough.

Non-compliance deadline approaching and Reebok launch due.

Interesting...🤔

Fair enough Northern,

So what's your solution?

A complete Board clear out? If so, who will takeover that understands the detail of the pipeline, it's contacts and can progress the business.

Everyone suggests Professor Hargreaves but has he the appetite for it, given his other commitments?

It's cheap talk to criticise Suzy, but not many people seem to post an alternative.

For the record , my preference would be Stella as CEO, with Suzy reverting to CSO.

At the risk of turning this into a serious debate (!), I'm not sure Suzy is the problem, it's the freeloading inner circle that need culling.

Personally I really like Suzy's lab/evaluation strategy, which I believe will pay off. She's an accomplished scientist and a fantastic ambassador for women's health.

The problem is the arrogance of Cox towards shareholders and the failure of Treharne/Tralau-Stewart to deliver any monetary value.

If Stella and/or Professor Hargreaves get involved to clear out the deadwood, then we'd all have a renewed sense of optimism.

EUDA up to $1.55 (+5.44%)

The market seems to think the merger will happen.

Trouble is, with such a modest upfront payment for 201, it won't be a big SP rise. Plus, they'll be plenty of 10% flippers of placement shares to hold us back.

I think we're stuck at sub 10p for the foreseeable future, unless Cytolytix gets funded for P1 with an upfront payment.

However, Cox and Treharne haven't managed to sell a bean in three years, so I ain't hopeful.

Stella for me. 🍺

Apologies, long version;

https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=317972221&type=HTML&symbol=LUCY&cdn=01160c67c9916163d27a0570fd877106&companyName=Innovative+Eyewear+Inc.&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2024-01-05

Form 8-k

Internal promotion and the IngenioSpec deal.

http://tinyurl.com/3bh3vbtj

"As compensation for his services, the Company shall pay Mr. Abondano a base salary of $140,000 per year. Mr. Abondano shall also have the right to receive a cash bonus of $30,000 at the end of any fiscal quarter in which the Company achieves $1,000,000 or more in E-commerce revenue"

That's an ambitious target!! 😁

Harrison Gross, CEO of Innovative Eyewear, said "We are pleased to have entered into a license agreement with IngenioSpec. This multi-year. non-exclusive license includes patents directed to a wide variety of smart eyewear features which we may include in our future products. We believe the combination of this IP with Innovative Eyewear's current portfolio of 63 owned and exclusively licensed patents and applications, provides a potential competitive advantage for us in the smart eyewear marketplace."

Market didn't like the news. 🙄

https://www.rttnews.com/3415014/innovative-eyewear-announces-license-agreement-and-patent-settlement-with-ingeniospec.aspx